

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/779,689	02/08/2001	Kiran M. Das	13257-00031	6769
75	90 11/26/2001			
Janet E. Reed, Saul Ewing Centre Square West 38th Floor			EXAMINER	
			JAMROZ, MARGARET E	
1500 Market Street Philadelphia, PA 19102			ART UNIT	PAPER NUMBER
			1644	1
			DATE MAILED: 11/26/2001	

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>		Application No.	Applicant(s)				
Office Action Summary		09/779,689	DAS, KIRAN M.				
		Examiner	Art Unit				
		Margaret E Jamroz	1644				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)	Responsive to communication(s) filed on	<u>_</u> ·					
2a) <u></u> □	This action is FINAL . 2b)⊠ This	s action is non-final.					
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)🛛	4)⊠ Claim(s) <u>1-15</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	5) Claim(s) is/are allowed.						
6)[6) Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8) Claim(s) 1-15 are subject to restriction and/or election requirement.							
Application	on Papers						
9)[] 7	The specification is objected to by the Examiner						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) ☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152) Section facsimile				

Application/Control Number: 09/779,689

Art Unit: 1644

DETAILED ACTION

1. The location of your application in the PTO has changed. To aid in correlating papers for this application, all further correspondence regarding this application should be directed to Megan Jamroz in Art Unit 1644, Technology Center 1600.

Restriction Requirement

- 2. Please Note: In an effort to enhance communication with our customers and reduce processing time, Group 1640 is running a Fax Response Pilot for Written Restriction Requirements. A dedicated Fax machine is in place to receive your responses. The Fax number is 703-308-4315. A Fax cover sheet is attached to this Office Action for your convenience. We encourage your participation in this Pilot program. If you have any questions or suggestions please contact Paula Hutzell, Ph.D., Supervisory Patent Examiner at Paula.Hutzell@uspto.gov or 703-308-4310. Thank you in advance for allowing us to enhance our customer service. Please limit the use of this dedicated Fax number to responses to Written Restrictions.
- 3. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
 - I. Claims 1-6 and 8, drawn to a method of treating or preventing ulcerative colitis comprising administering a recombinant protein; classified in Class 424, subclass 184.1.
 - II. Claims 1-2, and 4-7, drawn to a method of treating or preventing ulcerative colitis comprising administering phorbol-12-myristate-13-acetate; classified in Class 514, subclass 510.
 - III. Claims 1-2, and 4-7, drawn to a method of treating or preventing ulcerative colitis comprising administering monensin; classified in Class 514, subclass 2.
 - IV. Claims 1-2, and 4-7, drawn to a method of treating or preventing ulcerative colitis comprising administering methylamine; classified in Class 514, subclass 610.
 - V. Claims 9-11, drawn to a method of screening drugs, classified in Class 435, subclass 7.92.
 - VI. Claims 12-15, drawn to a diagnostic method for detecting diseases associated with an auto-antigen complex, classified in Class 435, subclass 7.1.

Application/Control Number: 09/779,689

Art Unit: 1644

4. Groups I-VI are different methods. The inventions as grouped in Groups I-VI are distinct, each from the other, because they represent different inventive endeavors as one does not suggest the other; therefore, each method is patentably distinct.

Claims I-IV recite compounds that are recombinant proteins, phorbol-12-myristate-13-acetate, monensin, or methylamine respectively. Recombinant proteins, phorbol-12-myristate-13-acetate, monensin, or methylamine differ with respect to their structures; one of ordinary skill in the art would not envision one in view of the other. In addition, they differ in mode of action; therefore, they have been set forth as groups irrespective of the format of the claims.

5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Species Election

6. Applicant is further required under 35 USC 121 (1) to elect a single disclosed species to which the claims would be restricted if no generic claim is finally held to be allowable and (2) to list all claims readable thereon including those subsequently added.

If Group I is elected, applicant is required to elect a specific method of treating or preventing ulcerative colitis comprising administering a specific recombinant protein, such as a protein having a functional fragment of hTM, disclosed in the specification on page 4, lines 1-11.

These species are distinct because the methods treating or preventing differ with respect to the specific recombinant protein administered; thus each specific method employing a specific recombinant protein represents patentably distinct subject matter.

7. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

Application/Control Number: 09/779,689

Art Unit: 1644

8. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Megan Jamroz whose telephone number is (703) 308-8365. The examiner can normally be reached Monday through Friday from 8:00 AM to 4:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Margaret (Megan) Jamroz, Ph.D. Patent Examiner Technology Center 1600 November 20, 2001

CHRISTINA Y. CHAN
SUPERVISORY PATENT EXAMINER
GROUP 1800 16 KO